REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

NeoImmuneTech. Inc. (South Korea)

Main Activities: Biological Product (except Diagnostic) Manufacturing
Full name: NeoImmuneTech. Inc. Profile Updated: March 15, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

The company is a clinical-stage T cell-focused biopharmaceutical company. The Company is engaged in the discovery and development of immuno-therapeutics. The Company was established on January 29, 2014. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on March 16, 2021.

Headquarters
2400 Research Boulevard, Suite 250
Brockville, Ontario;

Contact Details: Purchase the NeoImmuneTech. Inc. report to view the information.

Website: http://neoimmunetech.co.kr

Basic Information
Total Employees:
Purchase the NeoImmuneTech. Inc. report to view the information.
Outstanding Shares:
Purchase the NeoImmuneTech. Inc. report to view the information.
Registered Capital:
Purchase the NeoImmuneTech. Inc. report to view the information.
Financial Auditors:
Purchase the NeoImmuneTech. Inc. report to view the information.
Incorporation Date:
January 29, 2014
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Purchase this report to view the information.
Chief Financial Officer
Ownership Details
Purchase this report to view the information.
21.2%
Purchase this report to view the information.
5.7%
Purchase this report to view the information.
0.13%
Purchase this report to view the information.
0.1%
Subsidiaries
Neoimmunetech, Inc.
100%
Company Performance
Financial values in the chart are available after NeoImmuneTech. Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency USD. Absolute financial data is included in the purchased report.
Total operating revenue
0%
Operating profit (EBIT)
0.71%▲
EBITDA
1.6%▲
Net Profit (Loss) for the Period
-1.95%▼
Total assets
-30.04%▼
Total equity
-30.9%▼
Return on Equity (ROE)
-15.96%▼
Debt to Equity Ratio
0.47%▲
Quick Ratio
-0.97%▼
Cash Ratio
-0.51%▼

Similar companies

Shaperon Co.,Ltd.
 
Eutilex Co.,Ltd.
Celemics, Inc.
 
Bio Solution Co.,Ltd.
Samsung Biologics Co., Ltd.
 
Janssen Vaccines Corp.
U2Bio Co. Ltd.
 
Bioplus Co., Ltd.
GenoFocus, Inc.
 
T&R Biofab Co.,Ltd.

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo